About aligos therapeutics inc - ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
ALGS At a Glance
Aligos Therapeutics, Inc.
1 Corporate Drive
South San Francisco, California 94080
| Phone | 1-800-466-6059 | Revenue | 2.19M | |
| Industry | Pharmaceuticals: Major | Net Income | -24,193,000.00 | |
| Sector | Health Technology | Employees | 82 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALGS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 42.144 |
| Price to Book Ratio | 1.075 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.223 |
| Enterprise Value to Sales | 8.886 |
| Total Debt to Enterprise Value | 0.27 |
ALGS Efficiency
| Revenue/Employee | 26,658.537 |
| Income Per Employee | -295,036.585 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.027 |
ALGS Liquidity
| Current Ratio | 3.903 |
| Quick Ratio | 3.903 |
| Cash Ratio | 3.671 |
ALGS Profitability
| Gross Margin | 57.457 |
| Operating Margin | -4,024.931 |
| Pretax Margin | -1,092.36 |
| Net Margin | -1,106.725 |
| Return on Assets | -29.973 |
| Return on Equity | -196.915 |
| Return on Total Capital | -41.148 |
| Return on Invested Capital | -156.013 |
ALGS Capital Structure
| Total Debt to Total Equity | 9.805 |
| Total Debt to Total Capital | 8.929 |
| Total Debt to Total Assets | 5.861 |
| Long-Term Debt to Equity | 2.848 |
| Long-Term Debt to Total Capital | 2.594 |